Amgen, Inc.

Copyright © 2024 WTVD-TV. All Rights Reserved.

Copyright © 2024 WTVD-TV. All Rights Reserved.

EFPIA highlights EU's roadmap for precision oncology to address rising cancer burden, despite forecasted mortality rate declines. Stakeholder roundtable in Brussels aims to improve personalized cancer treatment. EU initiatives, including AI-powered cancer care and the DigiONE pilot, aim to advance precision medicine. A gold-standard cancer data management system is necessary for innovative precision medicine access, emphasizing standardized data formats, robust privacy, and professional education.

Big pharma's patent cliff presents a $200 billion opportunity for biosimilar developers, especially with biologics. Five companies—Alvotech, Biocon Biologics, Celltrion, Formycon, and Samsung Bioepis—are highlighted for their biosimilar developments and partnerships, aiming to capitalize on this market shift. The biosimilar market is projected to grow significantly, reaching $150.26 billion by 2033, driven by FDA regulations and demand for affordable treatments.

Amgen plans to invest $1 billion in expanding its Holly Springs, NC, facility, adding a second multi-drug substance manufacturing plant and 370 jobs. This brings the total site investment to over $1.5 billion and employment to 725 by 2032. The expansion aims to meet global demand for life-saving medications and is supported by partnerships with local, regional, and state entities.

Amgen Inc. to expand biologics manufacturing in Holly Springs, creating 370 jobs and investing $1 billion in Wake County. The expansion reflects Amgen's commitment to innovation and North Carolina's skilled workforce. The project is supported by a Job Development Investment Grant (JDIG), expected to boost the state's economy by $3.59 billion over 12 years.

Amgen plans to invest $1.2 billion in Holly Springs, adding 370 jobs by 2032, to expand manufacturing capacity. The state approved a $6.5 million incentives package, reflecting Amgen's commitment to innovation and North Carolina's supportive business climate.

Amgen seeks to consolidate four pending BPCIA litigations against biosimilar companies in New Jersey federal court. The MDL Panel issued a briefing schedule on Amgen's motion to transfer, with responses due on December 9. Judge O'Hearn set a trial date for Amgen's case against Celltrion on April 7, 2025.

Amgen may announce expansion in Holly Springs, potentially adding hundreds of jobs, following a scheduled economic development announcement by Commerce Secretary Machelle Baker Sanders. The expansion could involve economic incentives and follows Amgen's 2021 plan to build a $550 million drug manufacturing plant in the town.

A biotech company in Holly Springs plans to announce a major expansion, potentially adding hundreds of jobs, with details expected on Thursday. The announcement will be made by Commerce Secretary Machelle Baker Sanders at the North Carolina Biotechnology Center. The expansion involves an existing biotech company, though specifics remain undisclosed. This follows recent expansions by Fujifilm Diosynth, Amgen, and CSL Seqirus in the area, highlighting Holly Springs' appeal for biotech companies.